亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

ABSTRACTS of ICPE 2022, the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, 26–28 August, 2022

药物流行病学 医学 家庭医学 妇科 药理学 药方
作者
Ferraro, Sara,Paoletti, Olga,Giometto, Sabrina,Amanda J. Neville,Convertino, Irma,Valdiserra, Giulia,Cappello, Emiliano,Bonaso, Marco,Bartolini, Claudia C.,Lorenzoni, Valentina,Turchetti, Giuseppe,Gini, Rosa,Fornai, Matteo,Hermien E. K. de Walle,Tuccori, Marco
出处
期刊:Pharmacoepidemiology and Drug Safety [Wiley]
卷期号:31 (S2): 3-628 被引量:11
标识
DOI:10.1002/pds.5518
摘要

Background: Biologic drugs for ulcerative colitis are recommended \nwhen conventional therapy fails. Real-world studies may provide relevant \ninformation for the optimization of care. \nObjectives: The objective of the study was to describe drug-utilization \nand Regional Health System use in patients with ulcerative colitis new \nusers of advanced treatment (biologic drugs). \nMethods: This descriptive, retrospective cohort study (EUPAS40896) \nwas performed using Tuscan healthcare administrative databases: the \ndrug-reimbursement database and the registries of hospital discharges, \nemergency department (ED) admission and specialist visits. \nWe extracted patients with the date of the first dispensation of a biologic \ndrug (index date) recorded between January 2015 and \nDecember 2019. We created one cohort for each drug of interest. \nWe included also patients with: age ≥ 18; five years of data before \nthe index date (look-back period) at least one year of follow-up; UC \ndiagnosis OR UC co-payment exemption code in the look-back or in \nthe follow-up OR a gastroenterological visit in the year before the \nindex date. We described: drug-utilization (history of conventional \ntherapy use, treatment coverage and switch/swap events); the number \nof patients with at least one admission to ED or hospitalization \nand the time free from the first event recorded. \nResults: We analyzed four cohorts of new-users of adalimumab \n(N = 239), infliximab (N = 175), 110 golimumab (N = 110), vedolizumab \n(N = 107). Almost all patients were treated with conventional \ntherapy prior to biologics. Adalimumab cohort showed the lowest proportion \nof patients with history of other biologics (N = 37; 15%), while \nvedolizumab cohort had the highest (N = 69; 65%). The mean coverage \nof biologic therapy exceeds 100% of treatment's days, except for \ninfliximab (94%). Twenty-four patients (22%) new users of golimumab \nswitched to another biologic drug (mostly infliximab). Among the \nother cohorts, switch/swap events occurred in 22 (13%) infliximab \npatients, and in 26 (11%) and 8 (8%) adalimumab and vedolizumab \npatients, respectively. Vedolizumab and infliximab cohorts had the \nhighest proportion of patients with at least one ED access (N = 43; \n40%) and one hospitalization (N = 61; 35%), respectively. Overall, we \ndidn't find relevant difference between the cohorts in the use of \nhealthcare facilities. The time to the first ED admission ranged from \n140 days (±104.04) for infliximab users to 176 (±107.71) for adalimumab \nusers. \nConclusions: The use of biologics seems to be in line with clinical \nrecommendation, with adalimumab being the most widely used as \nfirst choice. The occurrence of ED accesses and hospitalizations was \nalmost similar among the new users of biologic drugs for ulcerative \ncolitis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
coco关注了科研通微信公众号
8秒前
Copyright应助科研通管家采纳,获得10
10秒前
Copyright应助科研通管家采纳,获得10
10秒前
17秒前
小辣椒完成签到,获得积分10
18秒前
zhaodan完成签到,获得积分10
24秒前
NI完成签到 ,获得积分10
32秒前
哈哈完成签到,获得积分10
33秒前
guyuzheng完成签到,获得积分10
34秒前
coco发布了新的文献求助50
36秒前
37秒前
38秒前
爱听歌谷蓝完成签到,获得积分10
41秒前
魔幻的芳完成签到,获得积分10
47秒前
火星上的宝马完成签到,获得积分10
53秒前
58秒前
银河完成签到 ,获得积分10
59秒前
悲凉的忆南完成签到,获得积分10
59秒前
陈旧完成签到,获得积分10
1分钟前
欣欣子完成签到,获得积分10
1分钟前
1分钟前
1分钟前
yxl完成签到,获得积分10
1分钟前
孟子发布了新的文献求助10
1分钟前
可耐的盈完成签到,获得积分10
1分钟前
1分钟前
绿毛水怪完成签到,获得积分10
1分钟前
1分钟前
1分钟前
lsc完成签到,获得积分10
1分钟前
盐焗小崔发布了新的文献求助10
1分钟前
李爱国应助细腻的雅阳采纳,获得10
1分钟前
小fei完成签到,获得积分10
1分钟前
1分钟前
麻辣薯条完成签到,获得积分10
1分钟前
1分钟前
1分钟前
时尚身影完成签到,获得积分10
1分钟前
leoduo完成签到,获得积分0
2分钟前
流苏2完成签到,获得积分10
2分钟前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
The recovery-stress questionnaires : user manual 800
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7257526
求助须知:如何正确求助?哪些是违规求助? 8879447
关于积分的说明 18757098
捐赠科研通 6937915
什么是DOI,文献DOI怎么找? 3201074
关于科研通互助平台的介绍 2375192
邀请新用户注册赠送积分活动 2176937